What is Clarus Therapeutics Holdings Financial Strength?
Clarus Therapeutics Holdings has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Clarus Therapeutics Holdings did not have earnings to cover the interest expense.
Clarus Therapeutics Holdings's debt to revenue ratio for the quarter that ended in Jun. 2022 was 2.50.
As of today, Clarus Therapeutics Holdings's Altman Z-Score is 0.00.
Competitive Comparison of Clarus Therapeutics Holdings's Financial Strength
For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarus Therapeutics Holdings's Financial Strength Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Financial Strength distribution charts can be found below:
* The bar in red indicates where Clarus Therapeutics Holdings's Financial Strength falls into.
Clarus Therapeutics Holdings Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Clarus Therapeutics Holdings's Interest Expense for the
months ended in Jun. 2022 was $-2.02 Mil. Its Operating Income for the
months ended in Jun. 2022 was $-10.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.00 Mil.
Clarus Therapeutics Holdings's Interest Coverage for the quarter that ended in Jun. 2022 is
| Clarus Therapeutics Holdings did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Clarus Therapeutics Holdings's Debt to Revenue Ratio for the quarter that ended in Jun. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Clarus Therapeutics Holdings has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description
Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
| Thomas Mcnerney & Partners Lp |
10 percent owner |
45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402 |
| Kimberly M Murphy |
director |
101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602 |
| Elizabeth Cermak |
director |
1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517 |
| Prygocki Mark A Sr |
director |
C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258 |
| John Kenneth Amory |
director |
C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662 |
| Robert E. Dudley |
director, officer: Chief Executive Officer |
555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062 |
| Joseph Hernandez |
director |
C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
| Richard D Peterson |
officer: Chief Financial Officer |
1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309 |
| Frank Jaeger |
officer: Chief Commercial Officer |
CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662 |
| Steven A. Bourne |
officer: Chief Administrative Officer |
555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062 |
| Ffi Fund Ltd |
10 percent owner |
DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208 |
| Thomas, Mcnerney & Partners Ii L.p. |
10 percent owner |
45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402 |
| Thomas, Mcnerney & Partners Ii, Llc |
10 percent owner |
45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
| Tmp Nominee Ii, Llc |
10 percent owner |
45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
| Tmp Associates Ii Lp |
10 percent owner |
45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRXTQ has been successfully added to your